Hengchuang Frontier・Sai Leads Health | Grand Opening Ceremony of Hengsai Bio-Linkport R&D and Production Base

On August 15, 2025, the opening ceremony of the R&D and production base of Hengsai Biologicals in Lingang was held grandly in the 10th phase of Life Blue Bay Intelligence Park in Lingang New Area. With the theme of "Hengchuang Frontier, Sai Leads Health", the ceremony invited the Lingang Administrative Committee, industry experts, shareholders' representatives, partners, leaders of the park and all the staff of Hengsai Biologicals to witness this important moment together.

Prof. Ma Jun, Director, Harbin Institute of Hematology and Tumor ResearchHe tells the story of his study experience in the United States and Japan as one of the first batch of publicly-funded students after the reform and opening up of China. After returning to China, he returned to Harbin and founded the Institute of Hematology because of his love for patients, and devoted himself to the treatment and research of hematological diseases. Since the reform and opening up, international exchanges have driven the continuous development of China's oncology research, and now the gap between China and the U.S. in the field of innovative drugs is gradually narrowing, and in the field of biopharmaceuticals China is even catching up with the U.S., and a lot of innovative drugs, especially those for hematological oncology, originated from Shanghai.EBV infection is very common in China, and there is no effective clinical solution to the diseases related to EBV infection. We hope that the Hengsai team can make the DC vaccine for EBV on the market, so that more patients can benefit from it as soon as possible. Because everything is for innovation and everything is for patients.

Prof. Chunrui Li, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, ChinaHe talked about his involvement as a clinical PI in the launch of the world's first humanized CART product and China's first CART product for myeloma, as well as the process of cooperation with Dr. Liu Huining, the founder of Hengsai Biotechnology, from acquaintance to tacit understanding. The IIT study of KSD-101 monotherapy for EBV-associated relapsed and refractory hematologic tumors was designed very rigorously, and the in-hospital ethical approvals and patient enrollment were very smooth, and clinical efficacy was obtained beyond expectation.

Prof. Atsuhiko Hasegawa, Kyushu Cancer Center, JapanHe shared his experience in basic research and clinical application of DC vaccine, which is a safe and effective treatment modality and can be used in the treatment of many kinds of tumors. As the chief scientific advisor of Hengsai Biologicals, he has witnessed the process of Hengsai's DC vaccine from 0 to 1, to the maturity of the technology, and then to the clinical treatment, which is all condensed with the hard work of the team members and the understanding and support of the clinicians.

Mr. Ma Wanjun, Co-FounderFrom the perspective of investors, Hengsai highly affirmed the innovation of DC vaccine technology and the expandability of Eco-DC Vax technology platform, and reiterated Hengsai's original intention of insisting on doing a good job of making innovative and good medicines in the world.

Dr. Huining LiuAlthough it is hard to start a business, the simple wish of "letting tumor patients be cured painlessly" guided the team like a lighthouse all the way to persevere in developing the Eco-DC Vax technology platform independently, and now the company has become a global leader in the field of DC vaccines. The first pipeline KSD-101, as the world's first DC vaccine targeting EBV broad-spectrum, is also China's first original DC vaccine to obtain FDA IND approval, and the stunning clinical efficacy data have been presented in many international conferences, highlighting China's innovative strength in the field of immunotherapy. The fruitful results could not have been achieved without the support and professional guidance from Kyushu Cancer Center, Wuhan Tongji Hospital, Shanghai Ruijin Hospital, Fudan University Cancer Hospital, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences, Harbin Institute of Hematology, as well as the all-around support and help from Lingang Administrative Committee, Lingang Fengxian Company and various investors.

The founder of Hengsai Bio and the guests cut the ribbon for the new base, and with the sound of the salute, the R&D and production base in Lingang was officially opened.

Base visit, let the guests feel the industry-leading R & D and production facilities and Hengsai to the product development and production process of excellence.

The R&D and production base of Hengsai Biologicals in Lingang has an area of more than 6,300 square meters, equipped with the top facilities in the industry, and the annual production capacity of DC vaccine can reach 5,000 human doses. Its opening marks the completion of the company's whole chain layout from scientific research to industrialization, which will effectively fill the gap of domestic DC vaccine industrialization and provide high-quality "Hengsai Solutions" for patients around the world.

Hengsai Bio will continue to take clinical needs as the lead, driven by scientific and technological innovation, and make every effort to develop safer, more effective and more accessible DC vaccine products to lead the new wave of cell therapy.